Novo has long sold a separate version of oral semaglutide for diabetes under the brand name Rybelsus, which the medicine ...

Central to the new report (PDF) are the JEC Democrats' findings that Trump increased his stock holdings in the pharmaceutical ...

In the fiercely competitive inflammatory bowel disease (IBD) market, Eli Lilly is making the case for its antibody Omvoh as a ...

Legendary actress Viola Davis’s newest role sees her getting real about shingles as a GSK spokesperson, reminding others that ...

Sanofi is gearing up for another major sports sponsorship in its home country, this time with the 2027 Tour de France. | The ...

Following a bumpy regulatory road that involved a refusal-to-file, ImmunityBio has won FDA approval to expand Anktiva into ...

In this week's episode of "The Top Line," we're looking at two companies building on recent successes and pursuing new ...

With a yearslong patent dispute between the two drugmakers finally put to bed—complete with a hefty settlement payout—United ...

Hot off a pair of key FDA green lights this summer, rare disease specialist Ultragenyx has wasted little time cashing in a ...

U.S.-based generic drugmaker Par Health has issued a voluntary recall of 22 lots of the direct thrombin inhibitor argatroban ...

Sanofi has avoided a European Union fine after antitrust regulators accepted its commitments to address the alleged ...

Some six years after scoring an initial FDA nod in neuromyelitis optica spectrum disorder, Roche’s IL-6 receptor agonist ...